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Abstract: The term idiopathic noncirrhotic portal hypertension (INCPH) has been recently 
proposed to replace terms, such as hepatoportal sclerosis, idiopathic portal hypertension, 
incomplete septal cirrhosis, and nodular regenerative hyperplasia, used to describe patients 
with a hepatic presinusoidal cause of portal hypertension of unknown etiology, characterized 
by features of portal hypertension (esophageal varices, nonmalignant ascites, porto-venous col-
laterals), splenomegaly, patent portal, and hepatic veins and no clinical and histological signs 
of cirrhosis. Physicians should learn to look for this condition in a number of clinical settings, 
including cryptogenic cirrhosis, a disease known to be associated with INCPH, drug administra-
tion, and even chronic alterations in liver function tests. Once INCPH is clinically suspected, 
liver histology becomes mandatory for the correct diagnosis. However, pathologists should be 
familiar with the histological features of INCPH, especially in cases in which histology is not 
only requested to exclude liver cirrhosis.
Keywords: idiopathic portal hypertension, obliterative portal venopathy, esophageal varices, 
splenomegaly
Historical background
In 1889, Guido Banti, an Italian pathologist, described a disease with splenomegaly and 
hypersplenism not associated with any known hematological disease.1 He considered 
the spleen as the primary site of the alterations leading to sclerosis of the splenic and 
portal veins. Over the years, it became clear that the patients described by Banti may 
have been affected by a variety of vascular and liver disorders, difficult to define, given 
the diagnostic facilities available at that time. In 1962, a syndrome distinct from both 
cirrhosis and extrahepatic obstruction of the portal vein was described in patients with 
portal hypertension from northern India.2 The disease was called noncirrhotic portal 
fibrosis.3 In 1965, Mikkelsen et al4 identified a concentric thickening of the portal vein 
and its radicles and called this condition “hepatoportal sclerosis” while Boyer et al5 
studying cases of noncirrhotic portal fibrosis in India adopted the term idiopathic portal 
hypertension. In the Western world, terms such as hepatoportal sclerosis, idiopathic 
portal hypertension, incomplete septal cirrhosis, and nodular regenerative hyperplasia 
(NRH) have been used over the years to describe the histological alterations observed 
in patients with portal hypertension in absence of cirrhosis, thus increasing the con-
fusion about the syndrome. Finally, in 2011, a group of European experts in portal 
hypertension proposed the term idiopathic noncirrhotic portal hypertension (INCPH) 
to be used in future collaborative studies.6
Correspondence: Oliviero Riggio
Department of Gastroenterology, Centro 
di Riferimento per l’Ipertensione Portale., 
II Gastroenterologia, Dipartimento 
di Medicina Clinica, “Sapienza” 
Università di Roma, Viale dell’Università 
37, 00185 Rome, Italy
Tel +39 6 4997 2001
Fax +39 6 4453 319
Email oliviero.riggio@uniroma1.it
Journal name: Hepatic Medicine: Evidence and Research
Article Designation: REVIEW
Year: 2016
Volume: 8
Running head verso: Riggio et al
Running head recto: Idiopathic noncirrhotic portal hypertension
DOI: http://dx.doi.org/10.2147/HMER.S85544
Hepatic Medicine: Evidence and Research 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
82
Riggio et al
In Western countries, INCPH is considered a rare disease and 
few series of patients have been collected and described so far.7–10 
However, in our opinion, due to low level of clinical suspicion, 
INCPH may be missed or confused with more frequent diseases. 
For example, it is possible that in a patient with esophageal vari-
ces, mild or no alterations in liver function tests, and no evidence 
of etiological factors, the diagnosis of “compensated crypto-
genic cirrhosis” may be made without taking into consideration 
INCPH.  Moreover, INCPH may be frequently associated with 
a number of diseases and drug treatment and should be actively 
searched in these instances. Finally, evidence is increasing that 
among patients with chronic alanine aminotransferase (ALT)/
aspartate aminotransferase (AST) elevation of unknown origin, 
histological sings of INCPH can be found at liver biopsy, suggest-
ing the possibility of diagnosing INCPH at an early stage, even 
before the clinical evidence of portal hypertension.11,12
In this review, we will try to answer some clinical ques-
tions concerning the diagnosis of INCPH.
What is the clinical manifestation 
of INCPH?
The majority of patients with INCPH present in early adult-
hood with a complication of portal hypertension usually 
variceal bleeding. At the diagnosis, they present signs of portal 
hypertension (esophageal or gastric varices). Not infrequently, 
the patients have been referred to a hematologist because of 
thrombocytopenia and splenomegaly.13 Ascites may occur, more 
frequently as a transient phenomenon, consequent to other com-
plications, such as gastrointestinal bleeding and infections.7–9
Hepatic encephalopathy may also occur, more frequently as 
a subclinical cognitive impairment, but ~7%–8% of the patients 
experiences at least one episode of overt hepatic encephalopa-
thy.8 In INCPH, the cognitive impairment is mainly related to 
the presence of large portal-systemic shunts, either spontaneous 
or iatrogenic.14 Portal vein thrombosis is a common compli-
cation of INCPH.9,15 HIV infection and variceal bleeding at 
diagnosis8 have been reported as risk factors for PVT.
How can the diagnosis of INCPH 
be made?
INCPH is a hepatic presinusoidal cause of portal hyper-
tension of unknown etiology, characterized by features of 
portal hypertension (esophageal varices, nonmalignant 
ascites, porto-venous collaterals) and splenomegaly, 
with or without hypersplenism. Portal and hepatic veins 
should be patent. Usually, liver function is preserved and 
the hepatic venous pressure gradient (HVPG) is slightly 
elevated, according to the presinusoidal nature of portal 
hypertension.
No clinical or laboratory alterations are pathognomonic 
of INCPH. The diagnosis should be made at the end of a 
complete diagnostic workout, aimed at excluding other 
causes of portal hypertension. This should include a detailed 
medical history to investigate possible liver diseases; liver 
imaging to evaluate the patency of the splanchnic venous 
axis and rule out chronic portal vein thrombosis or obstruc-
tion of the hepatic veins; and appropriate laboratory tests to 
exclude chronic viral hepatitis B and/or C, nonalcoholic or 
alcoholic steatohepatitis, autoimmune hepatitis, hereditary 
hemochromatosis, Wilson’s disease, and primary biliary cir-
rhosis. Finally, a liver biopsy should be always included in 
the diagnostic flowchart of INCPH.
What are the histological findings 
in liver biopsy specimens from 
patients with INCPH?
Liver biopsy is essential in the diagnostic flowchart of 
INCPH to exclude the diagnosis of liver cirrhosis, severe 
fibrosis, and rule out liver diseases known to cause portal 
hypertension in absence of cirrhosis (Table 1). The biopsy 
sample can be obtained either via the percutaneous or the 
trans-jugular approach; however, the latter method requires 
more extensive supplies and experience, and generally yields 
smaller and fragmented tissue samples as compared to the 
percutaneous approach.
Table 1 Principal causes of noncirrhotic portal hypertension
Presinusoidal Sinusoidal Postsinusoidal
Idiopathic noncirrhotic portal hypertension Drug induced Budd–Chiari syndrome
Biliary diseases (primary biliary cirrhosis; primary sclerosing cholangitis) Alcoholic liver damage Veno-occlusive disease
Neoplastic and non-neoplastic occlusion of the portal vein Nonalcoholic steatohepatitis Hypervitaminosis A
Schistosomiasis Viral hepatitis Primary vascular malignancies 
Polycystic disease Amyloid Epithelioid hemangioendothelioma and 
angiosarcoma Arteriovenous fistulas Infiltrative diseases 
Congenital hepatic fibrosis Visceral leishmaniasis
Gaucher’s disease
Acute fatty liver of pregnancy 
Hepatic Medicine: Evidence and Research 2016:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
83
Idiopathic noncirrhotic portal hypertension
Although there are no pathognomonic histopathologic 
features of INCPH, a number of microscopic lesions, 
both within portal tracts and in the liver parenchyma, 
are frequently associated with this condition. These are 
highlighted using hematoxylin and eosin, reticulin stain, 
and at least one connective tissue stain (ie, Picrosirius red, 
Masson trichrome, Elastic-Van Gieson) are performed on 
biopsy samples.6 Lesions observed at the level of portal 
tracts include 1) obliterative portal venopathy (or phlebo-
sclerosis), defined as obliteration or stenosis, with fibrosis 
or medial hypertrophy of portal vein branches, generally 
affecting medium-sized and preterminal portal veins 
 (Figure 1A–C); 2) portal fibrosis (Figure 1A) with portal 
tracts that are often small and rounded, without inflam-
mation; 3) paraportal shunting vessels, that is, dilated, 
thin-walled aberrant vascular channels herniating from 
the portal tracts into the surrounding parenchyma (Fig-
ure 1D); 4) portal venules dilatation, that is, enlarged portal 
branches which are at least three times greater than the size 
of the bile duct (Figure 1E); and 5) increased number of 
portal vascular channels (Figure 1F). Interestingly, oblit-
erative portal venopathy can be observed in liver biopsies 
even before the appearance of signs of portal hypertension. 
Thus, it is important to recognize this lesion on histology 
and follow-up subjects afterward.11
The liver parenchyma frequently shows sinusoidal dilata-
tion, defined as a sinusoidal lumen that is wider than one liver 
cell plate.16 This alteration generally affects multiple lobules 
within liver biopsy specimens and is associated with a thin 
rim of perisinusoidal fibrosis (Figure 2A). In the setting of 
NCPH, sinusoidal dilation is interpreted as a nonspecific 
feature of impaired portal venous flow. A less frequent find-
ing, which can be observed in liver biopsies, is NRH defined 
as parenchymal micronodular transformation, due to the 
presence of areas of hyperplastic hepatocytes alternating 
with atrophic, compressed liver plates, in the absence of 
fibrous septa.17 NRH is often a subtle change, which can 
be highlighted by reticulin stain (Figure 2B). Less frequent 
findings, which can be observed in INCPH, include evidence 
of organizing thrombosis of portal vein branches within 
medium-sized and large portal tracts (Figure 2C) and small 
platelet deposits in the sinusoids (Figure 2D). These findings 
are in line with the presence of an obstructive portal micro-
vasculopathy as the main pathogenic mechanism of INCPH, 
which, in turn, would cause liver nodular hyperplasia, as a 
consequence of focal liver ischemic damage.17
A B
C D
E F
*
Figure 1 Histologic features of the portal tracts in INCPH.
Notes: (A) Obliterative venopathy: portal vein with a reduced lumen (arrow) within a fibrotic portal tract; hematoxylin and eosin stain, original magnification ×10. (B) 
Obliterative venopathy: a fibrotic portal tract (white arrow) with a rounded contour and a small portal branch showing a thickened wall (arterialization): hematoxylin and 
eosin stain, original magnification ×20 (C) Obliterative venopathy: immunostain with antismooth muscle actin antibodies highlights smooth muscle cells hyperplasia in portal 
vein branch arterialization (asterisk); original magnification ×20. (D) Paraportal shunt: dilated, thin-walled portal vascular channel herniating into the surrounding parenchyma 
(asterisk); picrosirius red stain, original magnification ×10. (E) Marked portal vein dilation: the enlarged portal branch (asterisk) is at least three times greater than the size of 
the bile duct; picrosirius red stain, original magnification ×20. (F) Increased number of portal vascular channels (arrows); hematoxylin and eosin stain, original magnification ×10.
Abbreviation: INCPH, idiopathic noncirrhotic portal hypertension.
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How uncommon is INCPH in the 
Western world?
INCPH is more prevalent in developing countries and 
socioeconomically disadvantaged individuals.4,9,18,19 In 
India, INCPH accounted for 23% of patients with portal 
hypertension in 1980s but only 5.6% more recently.13,20 In 
Japan, the incidence rate of INCPH was 0.75/106 popula-
tion/year in 1985.21 Two more recent Japanese nationwide 
epidemiological surveys collected 322 patients treated in 
2,208 departments in 1998 and 229 patients treated in 1,885 
departments in 2004.22 In Europe and US, this condition is 
more prevalent in female (M:F=1:3), while in India it seems 
to be predominant in male sex.23 In the Western world, 
INCPH might be responsible for only 3%–5% of cases of 
portal hypertension.6
Bacterial infection of the gut with repeated septic embo-
lization and subsequent obstruction of small portal veins 
have been suggested to account for the high prevalence of 
INCPH in low socioeconomic areas with a high abdominal 
infection rate at birth and in early childhood. Improve-
ments in hygiene and living standards may explain the 
decreasing incidence of INCPH in India and Japan during 
the last decades, and the low prevalence of the disease in 
Western countries. However, the lack of a national database 
of patients with INCPH prevents an accurate calculation 
of its prevalence. Moreover, the low reported prevalence 
of this condition may be also explained by fact that liver 
cirrhosis is the main cause of portal hypertension in the 
West and is suspected and diagnosed more easily. Patients 
with INCPH are often classified as cirrhotic and it makes 
INCPH underestimated.
In which patients should INCPH be 
suspected?
In patients with compensated cryptogenic 
cirrhosis
The diagnosis of INCPH is based on the finding of portal 
hypertension with patency of the portal and hepatic veins in 
the absence of known causes of liver damage. These features 
coincide with those required for the diagnosis of cryptogenic 
cirrhosis. Usually, patients with INCPH have no signs of 
liver damage but transaminases or cholestasis enzymes could 
sometimes be elevated, while the liver synthetic capacity 
is usually preserved. This makes it difficult to distinguish 
between INCPH and compensated cirrhosis, in which liver 
function is still preserved. In both compensated cirrhosis 
and INCPH, the only laboratory abnormalities observed, 
such as anemia, leukopenia, and thrombocytopenia, may 
be the consequences of hypersplenism. At the abdominal 
ultrasound, the patients affected by INCPH show signs of 
portal hypertension and, because of the presence of NRH, 
the liver surface often appears irregular and indistinguishable 
from a cirrhotic liver.
Table 2 reports the comparison among clinical, labora-
tory, and ultrasound findings observed in patients with biopsy 
proven cryptogenic cirrhosis and INCPH. In patients with 
INCPH, the spleen diameter was significantly higher than 
in cirrhotic patients. INCPH patients have abnormal levels 
A B
C D
*
Figure 2 Histologic features of the liver parenchyma in INCPH.
Notes: (A) Sinusoidal dilatation with perisinusoidal fibrosis: dilated sinusoids are wider than one liver cell plate and are rimmed by a thin layer of collagen; picrosirius red 
stain, original magnification ×10. (B) Nodular regeneration: hyperplastic hepatocytes (asterisk) are surrounded by atrophic hepatocytes (arrow), in absence of fibrous septa; 
reticulin stain, original magnification ×10. (C) Organizing thrombus within a medium-sized portal branch; hematoxylin and eosin stain, original magnification ×5; (D) Platelet 
deposits within sinusoids (arrow); hematoxylin and eosin stain, original magnification ×100.
Abbreviation: INCPH, idiopathic noncirrhotic portal hypertension.
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Transient elastography may help to rule out cirrhosis. The 
finding of liver stiffness values lower than 12–14 kPa in the 
presence of clear signs of portal hypertension should raise 
the suspicion of INCPH30,31 as well as an increased spleen/
liver stiffness ratio.32
While portal hypertension due to cirrhosis is associ-
ated with an elevated HVPG in INCPH, the HVPG is not 
always elevated33 and the hemodynamic evaluation shows a 
significant difference between the HVPG and the portal vein 
pressure gradient consistent with a significant presinusoidal 
component of the portal hypertension.
The earlier considerations support the indication of liver 
biopsy in any patients with portal hypertension of unknown 
origin and patent hepatic and portal vein, especially if the 
patient has a preserved liver function and low stiffness value. 
The histological distinction between cirrhosis and INCPH 
is feasible based on the presence/absence of architectural 
alterations and significant fibrosis.
In patients affected by diseases known to 
be associated with INCPH
INCPH is frequently found in patients affected by the dis-
eases listed in Table 3. In some cases, INCPH is believed to 
be associated more with the treatment of the disease than the 
disease itself. Among 287 patients with INCPH collected in 
Europe, 152 (53%) had an associated disease. Strictly speak-
ing, the term “idiopathic” should be reserved to the cases in 
whom the associated diseases are absent. If we believe that 
portal hypertension is causally related to the presence of other 
diseases, the term noncirrhotic portal hypertension associ-
ated with (or secondary to) a given disease should be more 
appropriate. However, it has been suggested to use the term 
idiopathic also in patients with noncirrhotic portal hyperten-
sion associated with other disorders or medications.6 The 
uncertainty in the pathogenesis of INCPH and the similarity 
between the histological alterations observed in patients with 
portal hypertension associated or not with another disease 
probably justify this suggestion.
A practical consequence is that in patients affected by 
diseases known to be associated with INCPH, the active 
searching of signs of portal hypertension would be sug-
gested. However, the prevalence of INCPH among unselected 
patients with other disease is largely unknown. INCPH has 
been reported in 1% of HIV patients in India34 and in 4% of 
patients affected by primary immunodeficiency in Italy,35 but 
data on the prevalence are largely lacking.
On the other hand, once the diagnosis of INCPH is made, 
an active searching of the diseases listed in Table 3 would be 
Table 2 Comparison between patients with compensated 
cryptogenic and biopsy proven INCPH
Cryptogenic 
cirrhosis Class A 
Child–Pugh (n=19)
INCPH 
(n=20)
P
Age 58.7±10.6 45.8±16 0.0005
Sex (male/female) 6/13 13/7 0.03
Bilirubin (mg/dL) 1.13±0.6 1.2±1.1 0.8
Albumin (g/dL) 3.6±0.5 4.2±0.6 0.005
Patients with albuminemia 
<3.5 g%, n (%)
5 (26.3) 0 0.01
ALT, UI/L 86±222 33±20.6 0.29
Alkaline phosphatase (UI/L) 131.3±65.2 150.7±78.6 0.4
Cholinesterasis (UI/L) 4,504±1421 6,906±2153 0.0002
Patients with low 
cholinesterasis, n (%)
3 (16) 0 0.06
INR 1.31±0.3 1.21±0.37 0.35
Platelets (×103/μL) 115±46 103±74 0.54
Patients with esophageal 
varices, n (%)
14 (73) 15 (75%) 0.7
Clinical manifestation at 
diagnosis, n (%)
 Splenomegaly
 Ascites
 Variceal bleeding 
14 (74)
6 (31.5)
8 (42)
18 (90)
5 (25)
6 (30)
0.1
0.6
0.4
Abdominal ultrasound data
  Longitudinal spleen 
diameter (cm)
  Longitudinal liver 
diameter (cm)
  Portal vein 
diameter (mm)
14.3±2.8
13.2±1.23
12.8±2.5
17.7±5.7
15.54±2.95
14.9±3
0.03
0.009
0.04
Notes: Data presented as mean ± SD unless otherwise specified.
Abbreviations: ALT, alanine aminotransferase; INCPH, idiopathic noncirrhotic 
portal hypertension; INR, international normalized ratio; SD, standard deviation.
of liver synthesized proteins less frequently than cirrhotic 
patients. However, overlap exists making difficult the dis-
tinction between INCPH and cryptogenic cirrhosis in the 
single patient.
Imaging methods, such as computed tomography, mag-
netic resonance imaging, or ultrasound examination, have 
poor sensitivity and specificity for the diagnosis of INCPH 
and in distinguishing these patients from those affected 
by cirrhosis. Doppler ultrasonography will show a liver 
with an increased longitudinal diameter and heterogeneous 
parenchyma and nodular surface. When visible, regenerative 
nodules are small and isoechoic.24 Hyperechoic nodules have 
been reported in very rare cases of INCPH with NRH.25 On 
computed tomography, regenerative nodules remain isodense 
or hypodense in both arterial and portal venous phases, 
distinguishing NRH from focal nodular hyperplasia and 
 adenomas.26 At magnetic resonance, regenerative nodules 
appear hyperintense on T1-weighted images and iso- or 
hypointense on T2-weighted images.27–29
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useful. Again, the evolution of portal hypertension when an 
associated disease is diagnosed and treated is also unknown.
In patients with prothrombotic disorders
The relationship between INCPH and prothrombotic diseases 
is suggested by the high prevalence of hypercoagulability 
observed in the different series. In a French population 
described in 2002,9 a prothrombotic disorder (myeloprolif-
erative neoplasm, protein S or C deficiency, anticardiolipin 
antibodies) was found in 50% of patients. Moreover, the pres-
ence of obliterative portal venopathy in liver biopsies from 
patients with INCPH suggests the possibility that thrombotic 
events in the portal branches may be the anatomical base 
for INCPH development. Finally, patients with INCPH fre-
quently develop a portal vein thrombosis during the follow-
up, although this finding may be attributed to the low portal 
vein flow secondary to the presinusoidal increment of hepatic 
resistance. In the French series, 13 patients developed portal 
vein thrombosis after a median of 7.6 years from diagnosis. 
Similarly, a report from Turkey described extrahepatic portal 
vein thrombosis in seven of 34 (20%) patients with INCPH 
over a 5-year follow-up period.36 Anticoagulation has been 
consequently been proposed as a treatment for patients with 
INCPH.
The relationship between INCPH and hypercoagulation 
raises the possibility that a patient with portal hypertension 
attributed to portal vein thrombosis may be actually affected 
by an undiagnosed INCPH, preexisting to the development 
of portal vein thrombosis. Actually in ~25% of the patients 
with portal vein thrombosis, the underlying cause remains 
unknown despite the active searching of local or systemic 
diseases known to be associated with a thrombotic event. In 
patients with portal vein thrombosis of unknown origin, and 
also in those in whom a prothrombotic disease is diagnosed, 
liver biopsy is seldom performed and thus the diagnosis of 
INCPH as the preexisting condition for portal vein throm-
bosis may be missed.
In patients with chronic ALT/AST 
elevation of unknown origin
Two recent papers suggest that the histological lesions 
commonly described in patients with INCPH can also be 
observed in patients with chronic unexplained alteration of 
liver enzymes and no portal hypertension. Cazals-Hatem et 
al11 by reviewing 59 biopsies with histological diagnosis of 
obliterative portal venopathy (one of the most characteristic 
features of INCPH) found that among them 15 patients had 
no signs of portal hypertension at the initial observation. 
However, six of them developed portal hypertension dur-
ing the follow-up. More recently, Guido et al12 by review-
ing 482 liver biopsies from patients with chronic ALT/
AST elevation without cirrhosis and portal hypertension 
described histological alterations similar to those observed 
in patients with INCPH in 94 patients (19%). Interestingly, 
in this series, some patients were affected by diseases 
known to be associated with INCPH, such as autoimmune 
disorders (13% of patients) and prothrombotic disorders 
(6% of patients). These observations, if confirmed, suggest 
that patients with INCPH may be searched also among the 
patients with chronic liver function test abnormalities of 
unknown etiology and no signs of portal hypertension and 
that at least a proportion of these patients may develop portal 
hypertension later on.11
Again, the lack of awareness of this possibility as well as 
the lack of familiarity of the histological features of INCPH 
among the pathologists should contribute to the underestima-
tion of this condition.
Table 3 Diseases associated with INCPH
Disease type Disease name or cause
Acquired and 
congenital 
immunodeficiency
HIV15,37–42
Primary antibody-deficiency syndrome35,43,44
Genetic disorders Cystic fibrosis45–48
Adams–Oliver syndrome6
Turner’s disease6
Hematologic 
disease49–55
Myeloproliferative disorders (polycythemia 
vera, chronic myelogenous leukemia, essential 
thrombocythemia)
Myeloid metaplasia
Lymphoproliferative conditions (Hodgkin’s 
disease, non-Hodgkin’s lymphoma, chronic 
lymphocytic leukemia, and multiple myeloma)
Spherocytosis
Autoimmune 
disease56,57
Rheumatoid arthritis
Systemic lupus erythematosus
Systemic sclerosis
Scleroderma
Gut diseases Celiac disease58
Inflammatory bowel disease59
Drug and toxins60–63 Azathioprine, 6-thioguanine, arsenic as 
Fowler’s solution, oxaliplatin, busulfan, cytosine 
arabinoside, cyclophosphamide, thioguanine, 
bleomycin, chlorambucil doxyrubicin carmustine 
Thrombophilia9,51,64 Myeloproliferative neoplasm, protein S or C 
deficiency, antiphospholipid antibodies, lupus 
anticoagulant, factor V Leiden, prothrombin 
mutation
Abbreviation: INCPH, idiopathic noncirrhotic portal hypertension.
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Conclusion
INCPH is probably under recognized and underestimated 
in the Western world. Physicians should learn to search 
this condition in a number of clinical settings, including 
cryptogenic cirrhosis, diseases known to be associated with 
INCPH, drug administration, and even chronic alterations 
in liver function tests. Once INCPH is clinically suspected, 
liver histology became mandatory for the correct diagnosis. 
However, pathologists should be familiar with the histological 
features of INCPH, especially in cases in which histology is 
not only requested to exclude liver cirrhosis.
A number of issues remain to be clarified, including the 
etiology and pathogenesis of INCPH, its natural history, 
prognosis, and management. Cooperative studies are prob-
ably needed to solve these issues in a clinical condition, 
which, although underestimated, remains an infrequent 
disorder.
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